SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as retail traders are buzzing about a recent congressional disclosure of stock purchases, fueling speculation of potential government contracts. The community draws comparisons to Palantir ($PLTR) and is actively discussing chart patterns, anticipating a potential short squeeze. Bullish investors are highlighting the company's AI-driven solutions, with chatter revolving around potential gains amidst growing interest in AI for defense and security.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around a recovery, fueled by recent verification on Jupiter and Solflare. A token burn is anticipated at 2000 watchers, with community members expressing strong bullish sentiment and emphasizing the project's resilience. The focus remains on community-driven growth and long-term potential within the Solana ecosystem.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

TURB is trending due to a reported $53 million contract to deploy solar storage projects, sparking significant community discussion around a potential short squeeze and further upward momentum.  Traders are actively discussing entry and exit points, with some expressing regret over missed opportunities and others debating whether it is overbought. The stock's low float and the potential for a squeeze are key talking points.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARA is trending as traders discuss its potential for a short squeeze, given its high short interest, while others express concerns about the company's management and performance compared to its peers. Community members are debating the stock's correlation with Bitcoin and its future prospects in the crypto mining sector, with some highlighting its move into AI and data centers.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending as the company's latest earnings report and forward guidance exceeded expectations, driving optimism about its growth prospects. The community is discussing the potential for new locations and sustained revenue growth, while analysts are updating their price targets, adding to the bullish sentiment. Some are comparing BROS to other coffee companies, noting its ability to grow and compete in the current consumer environment.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo is trending amid community discussions around its potential for a short squeeze and past volatile behavior, with some speculating on upcoming earnings and potential for significant gains. However, concerns persist regarding dilution and its history as a potential pump-and-dump scheme. Bullish investors are comparing it to other high-flying stocks, while bears remain skeptical of its long-term prospects.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as investors discuss recent treasury acquisitions and potential for future growth, with community members highlighting specific tokens built on the Solana blockchain. Bullish sentiment is fueled by analysts' price targets and positive technical analysis, while others debate the network's capabilities and competitive landscape. Community members are closely watching key resistance levels and potential breakout points.

Trump For President

The TRUMP.X crypto is trending amid discussions about its potential connection to political events and figures, including Trump's policies and public appearances. Some community members express concerns about its performance compared to other cryptocurrencies like Bitcoin and Etherium, while others speculate on future price movements and potential investment opportunities. There are also discussions around the launch of a new DeFi token by the Trump family.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to a potential low float squeeze, with community members highlighting its small float and significant pre-market movement, drawing comparisons to other recent high-momentum stocks. Some traders suggest it may be overbought, while others point to insider ownership and potential for further gains, creating active discussion around its short-term trajectory and long-term value. The stock's high trading volume and past performance are fueling speculation about continued volatility and potential for both significant gains and losses.

$TRUFF is a revenue-sharing meme coin that combines fun, community engagement, and utility. Holders unlock tiered rewards based on token ownership, including revenue shares from bot fees and NFT drops, VIP event access, and exclusive perks. The ecosystem gamifies participation with evolving pig characters, fostering a strong community while offering tangible earning opportunities through its innovative, utility-driven platform.

Truffle Token

Truffle Token ($TRUFF.X) is gaining attention as community members express bullish sentiment and encourage others to join in, with many citing its potential for significant growth. Discussions frequently mention the ease with which it could pump and the advantages of purchasing it on Phantom. The token is being highlighted as a low market cap opportunity with substantial upside potential.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Rambus, Inc. (<a class="mention" data-mention="$RMBS" data-symbol-id="RMBS" href="https://stocktwits.com/symbol/RMBS" target="_blank">$RMBS</a>), a provider of Double Data Rate (DDR) memory interface chips, rose sharply early Tuesday, thanks to a positive analyst action.In a note published late-Tuesday, Baird analyst Tristan Gerra initiated coverage of Rambus with an&nbsp;‘Outperform’ rating and a $90 price target, which suggests scope for about 58% upside potential.The analyst noted that Rambus’ technology and IP is central to the artificial intelligence (AI)-driven performance increase in data centers. "Rambus is at the center of our 2025 semiconductor investment themes, which include AI memory, processors and optical systems," he said.&nbsp;Rambus has over 75% revenue exposure to data centers with AI becoming a major component of growth, Gerra said.&nbsp;He noted that the company is first to market with the October announcement of the "industry-first complete memory interface chipset for Gen 5 DDR5 RDIMM and next-generation MRDIMM." These bring much higher data transfer rates, lower latency and power consumption, he added.With the lineup, the company is poised to see a significant total addressable market expansion opportunity, Gerra said.The analyst sees major license deals with leading AI chip makers into the next year due to the HBM4 controller IP it announced in September that is expected to ramp in 2026.&nbsp;Rambus is poised to see significant growth, content increase, and share gains ahead, Baird said, adding that its data center chipset opportunity is estimated at $1.5 billion.<figure class="image"><a href="https://stocktwits.com/symbol/RMBS"><img style="aspect-ratio:631/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/rmbs_sentiment_5078361ebc.png" alt="rmbs-sentiment.png" width="631" height="138"></a><figcaption>RMBS sentiment and message volume November 26, 2024, as of 10:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, retailers turned ‘bullish’ (67/100) from a ‘neutral’ disposition a day ago, with message volume rising to ‘high’ level.At last check, Rambus was up 3.27% to $58.75.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Related Link:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

Rambus shares have underperformed the broader market and the semiconductor industry this year.

Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat

Rambus’ technology and IP is central to the artificial intelligence-driven performance increase in data centers, said Baird analyst Tristan Gerra.

Equity

Rambus’ technology and IP is central to the artificial intelligence-driven performance increase in data centers, said Baird analyst Tristan Gerra.




Expectations are muted as Bath &amp; Body Works, Inc. (<a class="mention" data-mention="$BBWI" data-symbol-id="BBWI" href="https://stocktwits.com/symbol/BBWI" target="_blank">$BBWI</a>), a retailer of personal care and home fragrance products, prepares to report its third-quarter results before the market opens on Monday.Analysts, on average, expect the Columbus, Ohio-based company to report third-quarter adjusted earnings per share (EPS) of $0.47 on net sales of $1.58 billion. This compares to the year-ago numbers of $0.48 and $1.56 billion, respectively. The company guided to flat to a 2.5% increase in net sales, translating to $1.56-$1.6 billion.&nbsp;Ahead of the results, Citigroup said it expects above-consensus adjusted EPS due to a slightly stronger gross margin and lower spending, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=BBWI">reported.</a> While conceding that the third quarter was another difficult quarter to drive sales, due to consumers remaining price-sensitive and the lack of big promotions to drive traffic, the firm said the second-half guidance is conservative enough.&nbsp;Citi believes that the fourth quarter is the best opportunity for the company to deliver upside to sales guidance this year. The firm has a Neutral rating and $35 price target for the stock. The risk/reward is skewed positive, going into the print, it said.Last week, JPMorgan analysts reduced its price target for the shares from $39 to $35.In early November, Bath &amp; Body Works announced a regular quarterly cash dividend of $0.20, payable on Dec. 6, to shareholders at the close of business on Nov. 22.The running quarter’s guidance is important, as it encompassed the holiday season. The forecast for this year’s industry-wide holiday sales is bright, with Bain &amp; Company<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bain.com/insights/2024-holiday-shopping-inside-latest-retail-sales-snap-chart/"> noting</a> a 5.4% year-on-year increase in October compared to September's 3.1% growth.&nbsp;"Santa’s sleigh has kicked into high gear for the start of the season," the firm said. Online sales grew 9.4%, in line with expectations, while in-store sales climbed a better-than-expected 4%, it added.Bath &amp; Body Works currently expects full-year net sales to fall by 2%-4%, with the 53rd week in 2023 representing a 100-basis-point headwind, and adjusted EPS of $3.02-$3.26.&nbsp;Bath &amp; Body Works shares have fallen about 27.33% for the year-to-date period.The average analysts’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tipranks.com/stocks/bbwi/forecast">price target&nbsp;</a>for Bath &amp; Body Works stock is $41.20, suggesting roughly 34% upside potential.<figure class="image"><a href="https://stocktwits.com/symbol/BBWI"><img style="aspect-ratio:637/130;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bbwi_sentiment_064b8def79.png" alt="bbwi-sentiment.png" width="637" height="130"></a><figcaption>BBWI sentiment and message volume November 24, 2024, as of 9:40 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment was ‘neutral’ (49/100), a deterioration from the ‘bullish’ mood that prevailed a day ago, while message volume was ‘normal.’The stock ended Friday’s session up 0.52% at $30.71.For updates and corrections email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks</a>

The holiday quarter got off to a promising start, with a strong October, going by Bain & Co.’s estimates

Bath & Body Works Analyst Cautious Ahead Of Q3 Print: Retail Sentiment Deflates

Price-sensitive consumers and a lack of big promotional drive dampen outlook for Bath & Body Works’ third quarter, Citi said.

Shares of Anavex Life Sciences Corp. ($AVXL) defied the broader market weakness and rallied on Thursday following a clinical trial readout.New York-based Anavex announced new data from the Phase 2b/3 study of its investigational drug candidate blarcamesin, administered as an once-daily oral formulation, demonstrating pre-specified clinical efficacy in people with early Alzheimer’s disease.&nbsp;The drug candidate, codenamed ANAVEX 2-73 worked through upstream activation of SIGMAR1, which is an integral membrane protein.Analysis of Phase 2b/3 data showed that over 48 weeks, blarcamesine&nbsp;significantly slowed clinical progression by 36.3% in the primary endpoint - Alzheimer’s Disease Assessment Scale-Cognitive 13-item, or ADAS-Cog13, scale, in the intention-to-treat&nbsp;analysis, the neurology-focused small-cap biopharma said.&nbsp;Juan Carlos Lopez-Talavera, Head of R&amp;D at Anavex, said, “The advantage of blarcamesine is that it is a small oral molecule that exerts clinical benefits on cognition and neurodegeneration and could be appealing because of its route of administration and good comparative safety profile.”The company said it is on track for regulatory submission of blarcamesine in Europe in the fourth quarter.The data was presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Madrid, Spain.Retail sentiment&nbsp;on Stocktwits has brightened following the data release,&nbsp;making&nbsp;Anavex stock the sixth-most trending&nbsp;ticker on Stocktwits.<figure class="image"><a href="https://stocktwits.com/symbol/AVXL"><img style="aspect-ratio:627/142;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/avxl_sentiment_b45388096b.png" alt="avxl-sentiment.png" width="627" height="142"></a><figcaption>AVXL sentiment and message volume October 31, 2024, as of 2:45 am ET | Source:&nbsp;Stocktwits</figcaption></figure>The&nbsp;sentiment meter trended in the “extremely bullish” (95/100)&nbsp;territory, improving from a “neutral” position a day ago, with message volume spiking to “extremely high.”One Stocktwits user&nbsp;sees scope for further upside in the near term. While noting that the short interest in the stock is 21%,&nbsp;the user said a short squeeze-fueled rally could materialize if the European Medicines Agency accepts the regulatory application for&nbsp;blarcamesine.<stembedurl>https://stocktwits.com/badprecog/message/590798832</stembedurl>As of 2:45 pm ET, Anavex shares rallied 16.29% to $6.64, having pulled back from an intraday high of $7.37. The stock has crossed the $7 threshold for the first time this year.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-to-report-q4-results-after-the-closing-bell-on-thursday/cJ2C2TSRBB">Apple Stock Slips Ahead Of Q4 Results As Analyst Loses Sleep Over Guidance: Retail Mood Stays Sour</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Anavex plans to file regulatory application for its Alzheimer's drug candidate in Europe.

Anavex Life Sciences Stock Spikes On Late-Stage Alzheimer’s Drug Trial Data, Retail Mood Upbeat

Anavex' once-daily drug candidate demonstrated pre-specified clinical efficacy in people with early Alzheimer’s disease. 

Shares of telehealth company Hims &amp; Hers Health Inc. (<a class="mention" data-mention="$HIMS" data-symbol-id="HIMS" href="https://stocktwits.com/symbol/HIMS" target="_blank">$HIMS</a>) fell over 8% pre-market on Thursday following a key update from the federal government on weight-loss drug supply.Late Wednesday, the U.S. Food and Drug Administration <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">announced</a> that Eli Lilly’s popular weight-loss and diabetes drugs, Mounjaro and Zepbound, are no longer in shortage after a two-year period where supply couldn’t meet skyrocketing demand.Both medications, which trigger the hormone GLP-1 to help curb appetite, are now available to meet projected national needs, according to the agency.Investors worry that the update could pose a headwind for telehealth companies like Hims &amp; Hers, which have capitalized on the shortages by offering compounded versions of GLP-1 drugs.These alternatives, produced by FDA-registered outsourcing facilities, are sold to customers unable to access originals such as Novo Nordisk’s (NVO) Wegovy or Lilly’s Zepbound.Under U.S. law, telehealth platforms are only allowed to manufacture these copycat drugs when the branded originals are in short supply.<figure class="image"><a href="https://stocktwits.com/symbol/HIMS"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/HIMS_sentiment_and_message_volume_Oct_3_pre_market_bdee8c8ba8.png" alt="HIMS sentiment and message volume Oct 3 pre-market" width="1314" height="320"></a><figcaption>HIMS sentiment and message volume Oct 3 pre-market</figcaption></figure>Still, retail sentiment for Hims &amp; Hers remained resilient on Stocktwits, where the ticker held a ‘bullish’ score (74/100) early Thursday.“It’s going to take a while for the market to realize this is not just a semaglutide company,” wrote one user, while another pointed out that Hims &amp; Hers never sold a compounded version of Tirzepatide (Lilly’s drug).<stembedurl>https://stocktwits.com/Hkaz34/message/587849299</stembedurl><stembedurl>https://stocktwits.com/BestRegards/message/587866562</stembedurl>Citi analysts pointed out that Hims &amp; Hers won’t be directly affected by the FDA’s decision, as it compounds semaglutide, the key ingredient in Novo Nordisk’s rival weight-loss drug, which is still on the FDA’s shortage list.&nbsp;However, they cautioned that the FDA’s announcement constrains Hims &amp; Hers's future total addressable market and "portend[s] a faster-than-anticipated resolution to shortages."&nbsp;Hims &amp; Hers is best known for selling treatments like hair-loss products and sexual-health medications like Viagra and Cialis.The company recently entered the weight-loss space as GLP-1 drugs gained popularity, offering compounded versions with the same active ingredient as Novo Nordisk’s Wegovy and Ozempic.In May, the company said its weight-loss business is expected to surpass $100 million in revenue by the end of 2025. This projection did not include the revenue potential of GLP-1 drugs, which could further bolster the company’s growth.Some analysts <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-after-eli-lilly-zepbound-discount/c7wEdA9Rco">have noted</a> that Hims &amp; Hers is growing at over 40% annually, even without significant contributions from these drugs.HIMS stock has nearly doubled in value this year, although Thursday’s pre-market drop reflects the market’s ongoing sensitivity to developments in the GLP-1 space.Editor's note: This article was updated with Citi's note on the potential impact of the FDA's statement on Hims &amp; Hers' business and addressable market.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/nkla-stock-surges-on-q3-deliveries/cJcGll6R3o">Nikola Stock Thunders Ahead After Impressive Q3 Electric Truck Deliveries, Attracts Retail Spotlight</a>For updates and corrections, email <a href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com.</a>

The move by Lilly is seen as a significant challenge to GLP-1 compounders, including Hims & Hers, which recently entered the weight-loss drug market. 

Hims & Hers Stock Slides After FDA Says Eli Lilly’s Weight-Loss Drug No Longer In Shortage, But Retail Shrugs Off Worries

Under U.S. law, telehealth platforms are only allowed to manufacture copycat weight-loss drugs when the branded originals are in short supply. 

Shares of telehealth company Hims &amp; Hers Health Inc. (HIMS) fell over 5% on Tuesday following <a href="https://stocktwits.com/news/markets/equity/eli-lilly-releases-single-dose-vials-of-weight-loss-drug-zepbound/c7wEcbCRcn">news</a> that Eli Lilly &amp; Co. (LLY) is now selling single-dose vials of its popular weight-loss drug Zepbound at a steep discount.Lilly’s Zepbound vials, priced at $399 per month, represent a 50% or greater discount compared to other incretin or GLP-1 medicines for obesity, as the company attempts to address ongoing supply shortages.The move by Lilly is seen as a significant challenge to GLP-1 compounders, including Hims &amp; Hers, which recently entered the weight-loss drug market.Citi analyst Daniel Grosslight described Lilly’s pricing strategy as a "shot across the bow" for compounders, emphasizing the company's efforts to protect patients from counterfeit or unsafe knock-off versions of the drug.Despite the potential threat from Lilly, analysts remain cautiously optimistic about Hims &amp; Hers' prospects. Needham, which recently initiated coverage of HIMS with a ‘Buy’ rating and a $24 price target, acknowledged the increased volatility associated with the company’s GLP-1 offerings but believes that the impact will ultimately be more positive than negative.Needham said Hims &amp; Hers continues to grow at over 40% annually, even without significant contributions from GLP-1 drugs, boasting over $1 billion in revenue with multiple growth opportunities.<figure class="image"><a href="https://stocktwits.com/symbol/HIMS"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/HIMS_sentiment_and_message_volume_Aug_27_11a0edd9ae.png" alt="HIMS sentiment and message volume Aug 27.png" width="1310" height="316"></a><figcaption>HIMS sentiment and message volume Aug 27</figcaption></figure>On Stocktwits, retail sentiment for HIMS shifted from ‘bearish’ to ‘neutral’ (53/100), with several watchers expressing confidence in the company's long-term growth potential beyond the GLP-1 segment.<stembedurl>https://stocktwits.com/Robinhoodboys/message/584240092</stembedurl>One user pointed out that GLP-1 drugs represent less than 10% of Hims &amp; Hers’ entire drug portfolio, highlighting the company’s diversified product mix.<stembedurl>https://stocktwits.com/ThinkVest/message/584245377</stembedurl>Earlier this month, Hims revealed it was set to buy a U.S.-based compounding pharmacy for approximately $31 million, in line with its strategy of offering copycat versions of popular weight-loss drugs, including those from Novo Nordisk (NVO).Despite the challenges posed by larger competitors like Lilly, Hims &amp; Hers’ strong Q2 performance, which exceeded Wall Street expectations, showed the beat was driven by surging demand for its weight-loss medicines.The company also raised its 2024 sales forecast to a range of $1.37 billion to $1.40 billion (from an earlier guidance of $1.20 billion to $1.23 billion), signaling confidence in its continued growth and market presence.Read Next: <a href="https://stocktwits.com/news/markets/equity/cava-stock-falls-after-key-insiders-sell-shares/c7wEcRaRcF">Cava Stock Plunges As CEO, Key Stakeholders Offload Shares Amid Record Highs: Is Retail Mood Souring?</a>&nbsp;&nbsp; &nbsp;

HIMS Stock Slides After Eli Lilly’s Discounted Single-Dose Zepbound Offering: Retail Investors Unfazed

Wall Street remains cautiously optimistic about Hims & Hers' prospects, with one analyst saying it continues to grow at over 40% annually even without significant contributions from GLP-1 drugs

Despite the potential threat from Lilly, Wall Street remains cautiously optimistic about Hims & Hers' prospects, with one analyst saying it continues to grow at over 40% annually even without significant contributions from GLP-1 drugs


Shares of fast-casual Mediterranean chain Cava Group (CAVA) dropped over 8% in pre-market trading on Tuesday, after closing at a record high in the previous session. &nbsp;The decline comes in response to an SEC filing that revealed key shareholders and top executives have been offloading significant portions of their holdings in the company.Artal International S.C.A., a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million. This sale comes over and above the 5.55 million shares that Artal already sold in the past three months.The move by Artal signals a potential shift in sentiment among early investors who have benefited from Cava’s meteoric rise since its IPO.<stembedurl>https://stocktwits.com/HeisenbergCap/message/584223663</stembedurl>Cava's leadership has also been cashing in on the company’s recent success. CEO Brett Schulman exercised his option to sell 201,504 shares, netting $24.9 million. Founder and Chief Concept Officer Ted Xenohristos also sold 98,490 shares, earning $12.4 million. Furthermore, three other directors collectively sold 11,500 shares.<stembedurl>https://stocktwits.com/mpier/message/584236225</stembedurl>On Stocktwits, retail sentiment stayed in the ‘neutral’ zone (52/100), with message volume surging, as watchers digested the development.<figure class="image"><a href="https://stocktwits.com/symbol/CAVA"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CAVA_sentiment_and_message_volume_Aug_27_premarket_0f309e0c1e.png" alt="CAVA sentiment and message volume Aug 27 premarket.png" width="1310" height="316"></a><figcaption>CAVA sentiment and message volume Aug 27 premarket</figcaption></figure>Cava has been a stand-out performer in the restaurant sector. Since its market debut in June 2023, the stock has soared nearly 230%, driven by a series of earnings beats, impressive same-store sales growth, and the successful launch of new menu items.Earlier this month, Cava reported better-than-expected Q2 results for 2024 and raised its full-year guidance.However, concerns about the company’s valuation have begun to surface. Cava’s price-to-earnings (P/E) ratio currently stands at an eye-popping 345.89, far exceeding that of industry giants like Chipotle Mexican Grill (53.65) and McDonald's Corp (25.26).&nbsp;Read Next: <a href="https://stocktwits.com/news/markets/equity/pzza-stock-rises-on-takeover-speculation/c7w36O5RcN">Papa John’s Stock Rises, Retail Buzz Grows As Analyst Note Sparks Takeover Speculations</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;

Cava's leadership has also been cashing in on the company’s recent success. 

Cava Stock Plunges As CEO, Key Stakeholders Offload Shares Amid Record Highs: Is Retail Mood Souring?

Artal International, a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million on Monday.

CAVA Stock Topples From Record High On Insider Sales: Is Retail Mood Souring?

Artal International, a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million on Monday.


Shares of fast-casual Mediterranean chain CAVA Inc. (CAVA) saw the highest jump in new retail followers on Stocktwits over the past 24 hours on Thursday, despite ending the session in the red due to profit-booking.Message volume related to the stock surged more than 575% to reach ‘extremely high’ (92/100) levels, as watchers eagerly discussed the company’s Q2 results, which comfortably beat Wall Street estimates on revenue and profit.Same-store sales grew by an impressive 14.4%, exceeding most expectations, while traffic increased by 9.5% during the quarter. This suggests that the restaurant chain is reportedly outperforming many of its peers in a challenging economic environment with cost-conscious consumers.The company highlighted that its grilled steak offering provided customers with "another reason to visit Cava and come back more often." Additionally, CAVA raised its full-year outlook for same-store sales, new location openings, and adjusted profit.At least four Wall Street brokerages have raised their price targets for CAVA, with Baird setting the highest at $125—representing more than a 12% upside from current levels. However, Barclays is the only brokerage so far with a target below current levels, at $95.Despite the stock's near-9% jump before the bell on Friday, retail sentiment on Stocktwits remained 'bearish' (41/100), though it showed slight improvement from the previous day.<figure class="image"><a href="https://stocktwits.com/symbol/CAVA"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CAVA_sentiment_and_message_volume_Aug_23_premarket_c017101953.png" alt="CAVA sentiment and message volume Aug 23 premarket.png" width="1310" height="316"></a><figcaption>CAVA sentiment and message volume Aug 23 premarket</figcaption></figure>Several pessimistic observers expressed concerns about the stock’s valuation.“$CAVA very overvalued imo and fake pump so big boys can unload to bag holders (retail). Caution,” warned one user.<stembedurl>https://stocktwits.com/stockswnoiz/message/583908678</stembedurl>“$CAVA Forward P/E is 300!+. That’s crazy!,” posted another bearish user.<stembedurl>https://stocktwits.com/ShortyMcShorterson/message/583891113</stembedurl>CAVA’s current market cap stands at $11.63 billion, with its valuation having skyrocketed over 167% since its stellar market debut in June 2023.The stock’s current price-to-earnings (P/E) ratio is 400.86, which significantly exceeds that of Chipotle Mexican Grill (CMG) at 52.38 and Domino’s Pizza Inc. (DPZ) at 25.59.Wedbush Securities believes CAVA is positioned to sustain positive transaction growth and gain market share over the long term, even relative to its growth peers, adding that the stock's premium valuation would be justifiable.But on Retail Street, investors are just not able to digest these views for now.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

The company highlighted that its grilled steak offering provided customers with "another reason to visit Cava and come back more often."

CAVA Stock’s Retail Following Jumps Most After Upbeat Q2 Results, But Sentiment ‘Bearish’

The restaurant chain is reaping the rewards of its grilled steak offering, which has been hit with customers. Shares are trading at all-time highs just 14 months after going public, but retail sentiment is still repressed.

CAVA Stock’s Retail Following Jumps Most After Upbeat Q2 Results

The restaurant chain is reaping the rewards of its grilled steak offering, which has been hit with customers. Shares are trading at all-time highs just 14 months after going public, but retail sentiment is still repressed.


BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

IWV
BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWV News

IWV BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF